What is PharmCADD?
Founded in 2019 and headquartered in Busan, PharmCADD operates at the vanguard of the digital health revolution. The company specializes in an integrated platform that combines artificial intelligence with physics-based modeling to streamline the de-novo therapeutic design process. By reducing the time and cost associated with traditional drug development, PharmCADD addresses critical inefficiencies in the pharmaceutical pipeline. Its market position is defined by a commitment to high-throughput screening and predictive analytics, enabling the rapid identification of viable drug candidates for complex disease states. As the industry shifts toward data-driven medicine, PharmCADD remains a pivotal entity in the evolution of precision therapeutics.
How much funding has PharmCADD raised?
PharmCADD has raised a total of $22.5M across 2 funding rounds:
Series A
$6.5M
Series B
$16M
Series A (2020): $6.5M with participation from KTB Network, Venture capital, and Daily Partners
Series B (2021): $16M, investors not publicly disclosed
Key Investors in PharmCADD
KTB Network
A prominent venture capital firm with a long-standing history of supporting high-growth technology and biotech enterprises across Asia.
Venture capital
An investment entity focused on providing strategic backing to early-stage and scaling companies within the innovation ecosystem.
Daily Partners
A specialized investment group known for its focus on the healthcare and life sciences sectors, providing both capital and operational expertise.
What's next for PharmCADD?
With the recent infusion of capital, PharmCADD is well-positioned to scale its proprietary AI-driven discovery engine and expand its international footprint. The company is expected to prioritize the enhancement of its physics-based simulation capabilities, which are essential for maintaining a competitive edge in the high-stakes field of drug discovery. Strategic objectives likely include the formation of new collaborative partnerships with global pharmaceutical giants and the acceleration of its internal pipeline of therapeutic assets. As the firm transitions from its earlier growth phases into a more mature enterprise-level operation, the focus will remain on validating its computational models through clinical-stage milestones and expanding its intellectual property portfolio to secure long-term market dominance.
See full PharmCADD company page
